Lipitor no help against Alzheimer’s, Pfizer says

updated 9:57 a.m. ET April 17, 2008

NEW YORK - Adding the popular cholesterol drug Lipitor to a commonly used Alzheimer’s disease treatment had no overall significant impact on patients with the progressive neurodegenerative condition, Lipitor’s maker Pfizer Inc. said on Thursday.

During an 18-month clinical trial, patients with mild-to-moderate Alzheimer’s disease taking the highest dose of Lipitor plus Pfizer’s Aricept showed no significant differences in cognition or global function — measures of the disease’s progression — compared with those taking a placebo plus Aricept.

The trial included 640 patients, making it the largest Alzheimer’s disease study involving the statin class of cholesterol drugs, Pfizer said. Researchers had hoped that statins could benefit Alzheimer’s disease patients.

Results were presented at the American Academy of Neurology meeting.

MORE FROM ALZHEIMER'S DISEASE

Alzheimer's disease Section Front

Vaccine failure deepens Alzheimer's mystery Exercise may slow Alzheimer's brain atrophy Scientists identify possible Alzheimer's gene Sticky protein may hold new Alzheimer's clue Promising drug fights Alzheimer's in three ways Bright lights slow dementia patients’ decline Early Alzheimer's patients speak up for others Regular aspirin use may cut Alzheimer's risk Painkillers don't slow dementia, study says Mid-life high cholesterol raises Alzheimer's risk Alzheimer's disease Section Front   Add Alzheimer's disease headlines to your news reader: